Gastroenterology

Gastroenterology

Volume 146, Issue 7, June 2014, Pages 1659-1668
Gastroenterology

Original Research
Full Report: Clinical—Alimentary Tract
Loss-of-Function of the Voltage-Gated Sodium Channel NaV1.5 (Channelopathies) in Patients With Irritable Bowel Syndrome

https://doi.org/10.1053/j.gastro.2014.02.054Get rights and content

Background & Aims

SCN5A encodes the α-subunit of the voltage-gated sodium channel NaV1.5. Many patients with cardiac arrhythmias caused by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS). We investigated whether patients with IBS have SCN5A variants that affect the function of NaV1.5.

Methods

We performed genotype analysis of SCN5A in 584 persons with IBS and 1380 without IBS (controls). Mutant forms of SCN5A were expressed in human embryonic kidney-293 cells, and functions were assessed by voltage clamp analysis. A genome-wide association study was analyzed for an association signal for the SCN5A gene, and replicated in 1745 patients in 4 independent cohorts of IBS patients and controls.

Results

Missense mutations were found in SCN5A in 13 of 584 patients (2.2%, probands). Diarrhea-predominant IBS was the most prevalent form of IBS in the overall study population (25%). However, a greater percentage of individuals with SCN5A mutations had constipation-predominant IBS (31%) than diarrhea-predominant IBS (10%; P < .05). Electrophysiologic analysis showed that 10 of 13 detected mutations disrupted NaV1.5 function (9 loss-of-function and 1 gain-of-function function). The p. A997T-NaV1.5 had the greatest effect in reducing NaV1.5 function. Incubation of cells that expressed this variant with mexiletine restored their sodium current and administration of mexiletine to 1 carrier of this mutation (who had constipation-predominant IBS) normalized their bowel habits. In the genome-wide association study and 4 replicated studies, the SCN5A locus was strongly associated with IBS.

Conclusions

About 2% of patients with IBS carry mutations in SCN5A. Most of these are loss-of-function mutations that disrupt NaV1.5 channel function. These findings provide a new pathogenic mechanism for IBS and possible treatment options.

Section snippets

Subjects

The Mayo Clinic Institutional Review Board approved the study. The mutation discovery cohort included patients (n = 584) aged 18–69 years recruited between February 2004 and July 2005 at the Mayo Clinic Rochester. The cohort used for replication of an independent genome wide association study (GWAS) for SCN5A (n = 1745) included additional patients from the United States (Mayo Clinic), and multicenter cohorts from Sweden, Italy, and Greece, as detailed in the Supplementary Materials and Methods

IBS Patient Cohort

The characteristics of the mutation discovery cohort are shown in Table 1. The median age was 49.5 years; they were predominately Caucasian (94%) women (83%). Diarrhea-predominant IBS (IBS-D, 25%) was more common than constipation-predominant IBS (IBS-C, 10%; Table 1). The remainder of the cohort was mixed-subtype IBS (31%) and those who could not be classified by our questionnaires. IBS patients from the GWAS replication cohorts had similar characteristics (Supplementary Table 2).

IBS Subjects With SCN5A Variations and Confirmation of the Findings in a GWAS

Thirteen of

Distinctive SCN5A Variations in a Subset of IBS Patients

A number of IBS-related putative genes have been identified, but almost all remain to be validated and each gene contributes to the pathophysiology in 1%–5% of patients.33 Patients with SCN5A mutations predisposing to cardiac conduction disorders also have a higher prevalence of IBS.20 A pilot study of 49 patients suggested a 2.0% prevalence of SCN5A mutations in IBS.21 In this 584-patient cohort (Table 1) we confirmed a 2.2% prevalence of SCN5A mutations in IBS subjects (Figure 1). In

Acknowledgment

The authors thank Kristy Zodrow for secretarial assistance.

References (42)

  • D.A. Drossman et al.

    United-States householder survey of functional gastrointestinal disorders—prevalence, sociodemography, and health impact

    Dig Dis Sci

    (1993)
  • A.C. Ford et al.

    IBS in 2010: advances in pathophysiology, diagnosis and treatment

    Nat Rev Gastroenterol Hepatol

    (2011)
  • Y.A. Saito et al.

    Familial aggregation of irritable bowel syndrome: a family case-control study

    Am J Gastroenterol

    (2010)
  • M.B. Bengtson et al.

    Irritable bowel syndrome in twins: genes and environment

    Gut

    (2006)
  • G. Farrugia

    Ionic conductances in gastrointestinal smooth muscles and interstitial cells of Cajal

    Annu Rev Physiol

    (1999)
  • A. Beyder et al.

    Targeting ion channels for the treatment of gastrointestinal motility disorders

    Ther Adv Gastroenterol

    (2012)
  • A. Akbar et al.

    Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents

    Aliment Pharmacol Ther

    (2009)
  • K. Muraki et al.

    Sodium currents in smooth muscle cells freshly isolated from stomach fundus of the rat and ureter of the guinea-pig

    J Physiol

    (1991)
  • P.R. Strege et al.

    Species dependent expression of intestinal smooth muscle mechanosensitive sodium channels

    Neurogastroenterol Motil

    (2007)
  • Z. Xiong et al.

    Fast Na+ current in circular smooth muscle cells of the large intestine

    Pflugers Arch

    (1993)
  • Y. Ou et al.

    SCN5A is expressed in human jejunal circular smooth muscle cells

    Neurogastroenterol Motil

    (2002)
  • Cited by (106)

    • Latest Insights on the Pathogenesis of Irritable Bowel Syndrome

      2021, Gastroenterology Clinics of North America
    • Frequency of Irritable Bowel Syndrome in Patients with Brugada Syndrome and Drug-Induced Type 1 Brugada Pattern

      2021, American Journal of Cardiology
      Citation Excerpt :

      SCN5A missense mutations (mostly loss-of-function) were present in 13 (2.2%) patients with IBS.6 A greater proportion of patients with SCN5A mutation met criteria for IBS-C than for IBS-D. SCN5A loss-of-function mutations in patients with IBS have been shown to generate NaV1.5 currents of smaller density and reduced mechanosensitivity.6 Two out of 7 patients with BrS/DI-Type 1 BrP and SCN5A/SCN1B variants in our study population (Patients 1 and 3 in Table 2) had loss-of-function SCN5A variant (p.Phe1293Ser) and IBS-C. Interestingly, this particular SCN5A variant has been previously reported in patients with IBS-C and proposed to have a mechanistic role in the pathophysiology of IBS.25,26

    • Biophysical mechanisms of myocardium sodium channelopathies

      2024, Pflugers Archiv European Journal of Physiology
    View all citing articles on Scopus

    Conflicts of interest This author discloses the following: Michael Ackerman has been a consultant for Boston Scientific, Medtronic, and St. Jude Medical; and collects royalties from Transgenomic (FAMILION). The remaining authors disclose no conflicts.

    Funding Supported by The Center for Clinical and Translational Sciences (CTSA) and National Institutes of Health grant DK52766, the Mayo Clinic Center for Cell Signaling in Gastroenterology (National Institute for Diabetes and Digestive and Kidney Diseases: P30DK084567), the Mayo Clinic Windland Smith Rice Comprehensive Sudden Cardiac Death Program, and the Swedish Research Council (VR 2010-2976).

    Authors share co-first authorship.

    §

    Authors share co-senior authorship.

    View full text